...
xncr-img

Xencor Inc, Common Stock

XNCR

NMQ

$23.73

-$1.31

(-5.23%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.75B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
970.27K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.66
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$15.31 L
$27.24 H
$23.73

About Xencor Inc, Common Stock

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameXNCRSectorS&P500
1-Week Return-6.06%-2.06%-0.55%
1-Month Return2.33%-1.92%2.72%
3-Month Return13.81%-10.4%7.66%
6-Month Return22.07%-4.6%10.15%
1-Year Return15.36%4.06%27.53%
3-Year Return-39.17%1.94%32.31%
5-Year Return-38.09%36.48%89.2%
10-Year Return45.58%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue156.70M122.69M275.11M164.58M168.34M[{"date":"2019-12-31","value":56.96,"profit":true},{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":61.19,"profit":true}]
Cost of Revenue118.59M169.80M7.49M8.80M253.60M[{"date":"2019-12-31","value":46.76,"profit":true},{"date":"2020-12-31","value":66.96,"profit":true},{"date":"2021-12-31","value":2.95,"profit":true},{"date":"2022-12-31","value":3.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit38.11M122.69M275.11M164.58M(85.26M)[{"date":"2019-12-31","value":13.85,"profit":true},{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":-30.99,"profit":false}]
Gross Margin24.32%100.00%100.00%100.00%(50.65%)[{"date":"2019-12-31","value":24.32,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.65,"profit":false}]
Operating Expenses142.88M199.49M231.34M247.05M306.98M[{"date":"2019-12-31","value":46.54,"profit":true},{"date":"2020-12-31","value":64.99,"profit":true},{"date":"2021-12-31","value":75.36,"profit":true},{"date":"2022-12-31","value":80.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income9.53M(76.80M)43.77M(82.47M)(138.64M)[{"date":"2019-12-31","value":21.77,"profit":true},{"date":"2020-12-31","value":-175.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-188.44,"profit":false},{"date":"2023-12-31","value":-316.77,"profit":false}]
Total Non-Operating Income/Expense31.28M14.73M39.71M32.78M31.94M[{"date":"2019-12-31","value":78.77,"profit":true},{"date":"2020-12-31","value":37.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.55,"profit":true},{"date":"2023-12-31","value":80.43,"profit":true}]
Pre-Tax Income27.19M(69.33M)82.63M(54.51M)(120.44M)[{"date":"2019-12-31","value":32.9,"profit":true},{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-65.97,"profit":false},{"date":"2023-12-31","value":-145.76,"profit":false}]
Income Taxes312.00K(5.79M)(7.49M)673.00K5.81M[{"date":"2019-12-31","value":5.37,"profit":true},{"date":"2020-12-31","value":-99.71,"profit":false},{"date":"2021-12-31","value":-128.91,"profit":false},{"date":"2022-12-31","value":11.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes26.88M(63.54M)90.12M(55.18M)(126.25M)[{"date":"2019-12-31","value":29.82,"profit":true},{"date":"2020-12-31","value":-70.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-61.23,"profit":false},{"date":"2023-12-31","value":-140.09,"profit":false}]
Income From Continuous Operations26.88M(69.33M)82.63M(55.18M)(119.03M)[{"date":"2019-12-31","value":32.52,"profit":true},{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-144.05,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income26.88M(63.54M)82.63M(55.18M)(126.09M)[{"date":"2019-12-31","value":32.52,"profit":true},{"date":"2020-12-31","value":-76.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-152.59,"profit":false}]
EPS (Diluted)0.45(1.21)1.35(0.93)(2.10)[{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-89.63,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-68.89,"profit":false},{"date":"2023-12-31","value":-155.56,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

XNCR
Cash Ratio 5.05
Current Ratio 6.23

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XNCR
ROA (LTM) -15.24%
ROE (LTM) -29.02%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XNCR
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XNCR
Trailing PE NM
Forward PE NM
P/S (TTM) 19.50
P/B 2.42
Price/FCF NM
EV/R 15.22
EV/Ebitda NM
PEG NM

FAQs

What is Xencor Inc share price today?

Xencor Inc (XNCR) share price today is $23.73

Can Indians buy Xencor Inc shares?

Yes, Indians can buy shares of Xencor Inc (XNCR) on Vested. To buy Xencor Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XNCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Xencor Inc be purchased?

Yes, you can purchase fractional shares of Xencor Inc (XNCR) via the Vested app. You can start investing in Xencor Inc (XNCR) with a minimum investment of $1.

How to invest in Xencor Inc shares from India?

You can invest in shares of Xencor Inc (XNCR) via Vested in three simple steps:

  • Click on Sign Up or Invest in XNCR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Xencor Inc shares
What is Xencor Inc 52-week high and low stock price?

The 52-week high price of Xencor Inc (XNCR) is $27.24. The 52-week low price of Xencor Inc (XNCR) is $15.31.

What is Xencor Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Xencor Inc (XNCR) is

What is Xencor Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Xencor Inc (XNCR) is 2.42

What is Xencor Inc dividend yield?

The dividend yield of Xencor Inc (XNCR) is 0.00%

What is the Market Cap of Xencor Inc?

The market capitalization of Xencor Inc (XNCR) is $1.75B

What is Xencor Inc’s stock symbol?

The stock symbol (or ticker) of Xencor Inc is XNCR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top